Amyloid PET imaging in clinical practice
Amyloid PET imaging in clinical practice
复制标题
DOI：
10.1136/practneurol-2019-002468
复制
发表时间：
2020-12-01
影响因子：
2.8
通讯作者：
Malhotra, Paresh A.
中科院分区：
文献类型：
--
作者：
Kolanko, Magdalena A.;Win, Zarni;Malhotra, Paresh A.
淀粉样蛋白正电子发射断层扫描 (PET) 成像能够体内检测大脑 Aβ 沉积，这是阿尔茨海默病的神经病理学标志之一。越来越多的证据支持其临床实用性，主要研究表明淀粉样蛋白 PET 成像可提高诊断准确性、增加诊断确定性并导致治疗改变。淀粉样蛋白成像工作组制定了适当的使用标准，通过预先定义淀粉样蛋白 PET 合理的某些场景来指导临床医生。本综述根据现有研究和我们自己的经验，为如何以及何时使用淀粉样蛋白 PET 提供了实用指南。我们讨论其三个主要的适当适应症，并用临床病例进行说明。在决定谁可以从淀粉样蛋白 PET 成像中受益时，我们强调多学科方法的重要性。最后，我们强调其解释中的一些实用要点和常见陷阱。
Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain A beta deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is increasing evidence to support its clinical utility, with major studies showing that amyloid PET imaging improves diagnostic accuracy, increases diagnostic certainty and results in therapeutic changes. The Amyloid Imaging Taskforce has developed appropriate use criteria to guide clinicians by predefining certain scenarios where amyloid PET would be justified. This review provides a practical guide on how and when to use amyloid PET, based on the available research and our own experience. We discuss its three main appropriate indications and illustrate these with clinical cases. We stress the importance of a multidisciplinary approach when deciding who might benefit from amyloid PET imaging. Finally, we highlight some practical points and common pitfalls in its interpretation.